- Login
- Register & Subscribe
- Language: EN FR DE
News
Therapeutic vaccine producer raises €13.1 million
Tuesday 9 March 2010
A French producer of therapeutic vaccines for cancer has raised €13.1 million from private and public sources in order to bring its lead product, a therapeutic human papillomavirus vaccine, into the clinic.
Country: France
Actelion receives FDA complete response letter for Zavesca
Tuesday 9 March 2010
Actelion Ltd said that it has received a complete response letter from the US Food and Drug Administration for its treatment for Niemann-Pick disease, Zavesca (miglustat). This means the agency cannot approve the application in its present form.
Country: Switzerland
Ark Therapeutics drops Cerepro appeal
Tuesday 9 March 2010
Ark Therapeutics Group Plc has dropped its appeal against a negative opinion from the European Medicines Agency for its gene therapy for brain cancer, Cerepro. It also announced that it is in talks about a possible takeover of the company. Ark disclosed the developments on 9 March 2010.
Country: United Kingdom
Zalutumumab fails to meet primary endpoint of overall survival
Tuesday 9 March 2010
Genmab A/S said that its antibody for head and neck cancer, zalutumumab, has failed to show overall survival in a Phase 3 study in which the drug was being tested in combination with best supportive care versus best standard care alone.
Country: Denmark
Recentin fails to meet primary endpoint in cancer trial
Monday 8 March 2010
AstraZeneca Plc said that its candidate drug, Recentin (cediranib), for patients with first-line metastatic colorectal cancer, failed to meet its primary endpoint of non-inferiority in progression-free survival in a Phase 2/3 trial.
Country: United Kingdom
Roche and Biogen Idec suspend RA trials with ocrelizumab
Monday 8 March 2010
The Roche Group and Biogen Idec of the US have suspended clinical trials of the humanized anti-CD20 monoclonal antibody, ocrelizumab, in four rheumatoid arthritis trials because of safety issues. The drug was in Phase 2 and 3 trials.
Country: Switzerland
Key milestones for BioAlliance in the second quarter
Friday 5 March 2010
BioAlliance Pharma SA is looking ahead to three possibly transforming events in the second quarter of 2010 that could secure its standing as a recognised specialty pharmaceutical company in Europe.
Country: France
Alzheimer’s drug fails at Phase 3
Thursday 4 March 2010
An investigational drug for patients with Alzheimer’s disease, Dimebon (latrepirdine), has failed in a Phase 3 trial because it could not show statistically significant improvements in patients compared with placebo for cognition and global function.
Country: United States
Intercell expects data in 2010 on vaccines against hospital-acquired infections
Wednesday 3 March 2010
Intercell AG expects to report data in 2010 on two late-stage vaccine candidates against hospital-acquired infections, conditions that have become serious in recent years because of bacterial resistance to marketed antibiotics.
Country: Austria
UCB looks to new products to offset loss of patent protection
Tuesday 2 March 2010
UCB expects that three recently launched drugs will drive the company’s growth for the next decade following a period of extensive restructuring.
Country: Belgium
Select a News Category
Recent Appointments
Catherine Bréchignac to join Sanofi-Aventis board
Monday March 8 2010
Ulf Jönsson joins PharmaDiagnostics
Monday March 8 2010
Jan van Heek appointed non-executive director at Amarin
Monday March 8 2010
Thomas Hecht to become chairman of Cytos Biotechnology
Monday March 8 2010
Benoît Battistelli elected president of the EPO
Monday March 8 2010